What Is Whole Blood and When Is It Used?

Whole blood is exactly what it sounds like: a unit of blood collected from a donor and left intact rather than being separated into its individual parts. It contains red blood cells, white blood cells, platelets, plasma proteins, antibodies, and electrolytes, all in the proportions the donor’s body produced them.¹ For decades, most hospitals broke donated blood into separate components and transfused each one individually. That practice is now being challenged by a growing body of evidence suggesting whole blood works better in certain emergencies, and its use in trauma care, helicopter ambulances, and even obstetric hemorrhage has expanded rapidly since the mid-2010s.

How Whole Blood Differs From Component Therapy

When you donate a standard unit of blood at most blood banks, that unit typically gets spun in a centrifuge and separated into packed red blood cells, platelet concentrates, and plasma. Hospitals then store each product under different conditions and transfuse them individually based on what a patient needs. If someone is anemic, they get red cells. If they’re bleeding because their blood won’t clot, they might get platelets or plasma. This approach, known as component therapy, became the default in the 1970s and has dominated transfusion medicine ever since.²

Whole blood skips that separation step. You get everything the donor had, in roughly the same ratios. That matters because a person who is hemorrhaging loses all blood components simultaneously. Giving them back one component at a time means a nurse or doctor has to juggle multiple bags, guess at the right ratios, and set up several IV lines, all while the patient is bleeding out. With whole blood, a single bag delivers red cells for oxygen carrying, platelets for clotting, and plasma proteins that help maintain blood pressure and vascular integrity.

Why It Fell Out of Favor and Why It Came Back

The shift away from whole blood happened gradually. During World War II, researchers first demonstrated that blood could be separated into dried plasma for treating shock on the battlefield.² By the 1970s, three forces pushed the medical world firmly toward component therapy: fears about infectious disease transmission (particularly HIV and hepatitis in later decades), advances in blood fractionation technology, and the financial incentive to turn one donation into multiple saleable products. The shift happened with surprisingly little clinical evidence supporting it.

The pendulum started swinging back during the wars in Iraq and Afghanistan. Military surgeons noticed that fresh whole blood given to severely injured soldiers on the battlefield appeared to improve survival compared to the component approach.³ Those battlefield observations sparked renewed civilian interest. The U.S. military formally reintroduced whole blood in deployed settings in 2015, and the AABB (the main accrediting body for blood banks in the U.S.) endorsed its use in 2018. Since then, military and civilian providers worldwide have been progressively adopting it.⁴

The Evidence on Survival in Trauma

The strongest case for whole blood comes from trauma, where patients are losing large volumes of blood fast. An updated systematic review and meta-analysis pooling data from dozens of studies found that whole blood transfusion was associated with roughly a quarter reduction in 24-hour mortality compared to component therapy. In civilian trauma patients specifically, the absolute risk reduction was about 4.6 percentage points, meaning for every hundred severely bleeding patients treated, roughly five additional lives were saved. The benefit also held at 30 days. Patients receiving whole blood also needed fewer total units of transfused products.⁵

A separate meta-analysis of civilian trauma patients found a consistent pattern: those who received only component therapy had about 40% higher risk of death at 24 hours compared to those who received at least some whole blood. Patients given components alone also required more red blood cell units at both 6 and 24 hours.⁶

One surprising finding from the larger meta-analysis is that the mortality benefit did not show up in military settings. The authors noted substantial variability across studies, which likely reflects the very different conditions under which military transfusions happen: longer evacuation times, different injury patterns, and the common use of fresh warm donor blood in the field rather than cold-stored product. The civilian evidence is more consistent, but researchers are still working out exactly which patients benefit most.

Why Whole Blood Might Work Better

The simplest explanation is logistical: whole blood is faster and easier to give. In a chaotic trauma bay or the back of a helicopter, setting up one bag instead of three saves precious minutes. But there appears to be a biological advantage too. Animal research has shown that whole blood helps restore the endothelial glycocalyx, a delicate gel-like layer that lines blood vessels and controls what leaks through them. In severe hemorrhage, this layer gets stripped away, which causes fluid to pour out of the bloodstream into surrounding tissues. Whole blood and plasma both appear to protect and rebuild this lining, helping to reduce dangerous vascular leakage.⁷

There’s also a clotting advantage. When blood is separated and stored as individual components, the platelets often lose function or are stored under different conditions than the rest. In whole blood kept cold, the platelets remain in contact with the plasma and clotting factors they naturally interact with. The result is a product that, while not identical to blood circulating in your body, retains more of its original clotting ability than reconstituted components do.

Blood Clots and Safety Concerns

A reasonable worry is whether giving a product packed with clotting factors and active platelets might increase the risk of dangerous blood clots in trauma patients. A study of over 3,400 patients found the opposite: whole blood recipients actually had lower rates of venous thromboembolism than those who received component therapy (about 6% versus 10%). After accounting for the fact that whole blood patients tended to be more severely injured, whole blood remained protective against clots.⁸ The red blood cell transfusions used in component therapy, interestingly, were themselves associated with increased clot risk, which may partly explain the difference.

Transfusion reactions are a concern with any blood product. The two most serious types are acute lung injury related to transfusion and circulatory overload from too much fluid, both of which can cause the lungs to fill with fluid within hours of a transfusion.⁹ These risks apply to all blood products, not just whole blood. Modern mitigation strategies, including better donor screening and more careful volume management, have reduced both types of reactions across the board.

Low-Titer O Whole Blood as a Universal Product

One of the biggest practical barriers to whole blood has always been blood-type compatibility. In an emergency, you often don’t know the patient’s blood type. The solution that has gained traction is low-titer group O whole blood, or LTOWB. Group O blood can be given to patients of any blood type because it lacks the surface markers that trigger immune rejection. “Low titer” refers to screening the donor’s plasma to ensure it has low levels of antibodies that could react against other blood types. The result is a product that can be given to essentially anyone without waiting for a type-and-crossmatch.

Research examining outcomes across different blood groups has found that LTOWB appears safe for universal use.¹⁰ This is what has made the prehospital revolution possible: helicopter crews and ambulance teams can carry LTOWB without needing to know what blood type their next patient will be. It is currently the only practical option for transfusion before a patient reaches the hospital.⁴

Whole Blood Before the Hospital Arrives

Some of the most exciting applications involve getting whole blood to patients in the field, before they ever reach an emergency room. Norway has been a leader in this area. A survey of all helicopter emergency medical services and search-and-rescue bases in Norway found that every single one carries either LTOWB or blood components on board. The majority expressed a preference for whole blood specifically because it enables balanced transfusion in situations where time is critical and evacuation may be prolonged.¹¹

The logistical simplicity matters enormously in this setting. A flight paramedic working in a confined helicopter with turbulence and limited equipment cannot easily manage three separate blood products, each requiring different administration rates and monitoring. A single unit of whole blood simplifies everything. Blood banks supporting these programs reported favorable experiences with implementation, suggesting the supply chain challenges, while real, are manageable.

Use Beyond Trauma

Whole blood isn’t limited to gunshot wounds and car accidents. Postpartum hemorrhage, which is severe bleeding after childbirth, is one area where early adopters have started using LTOWB. Two institutions reported their initial experiences treating obstetric patients with whole blood. Between them, seven patients received a total of 17 units of LTOWB, with no severe transfusion reactions and favorable outcomes in every case.¹² One institution designed its protocol specifically for emergency use during massive bleeding, while the other targeted high-risk patients with known placental abnormalities. A separate case report described what is believed to be the first use of cold-stored LTOWB in massive postpartum hemorrhage, with positive results.¹³

Pediatric cardiac surgery is another area with a long history of whole blood use. A landmark study in children undergoing complex heart operations found that those who received whole blood less than 48 hours old had significantly less postoperative bleeding than those given reconstituted components. In children under two years old, the difference was dramatic: bleeding was nearly cut in half.¹⁴ More recent work has continued to study whole blood as both a pump prime for the heart-lung machine and as the first-line transfusion product for infants needing surgery.¹⁵

The Shelf-Life Problem

Storage is whole blood’s Achilles’ heel. Unlike packed red blood cells, which can be refrigerated for up to 42 days, whole blood has a more limited useful life because its platelet function degrades over time. Research tracking the hemostatic quality of cold-stored whole blood found that platelet counts and platelet function dropped sharply at 7 days and again at 14 days. The good news is that the blood’s ability to initiate clotting and generate thrombin (a key protein in the clotting cascade) remained stable across the full 21-day shelf life, meaning the product still has value for oxygen-carrying capacity even after platelets have declined.¹⁶

Leukoreduction, which is the removal of white blood cells to reduce the risk of certain transfusion reactions, adds another layer of complexity. Standard leukoreduction filters also strip out most of the platelets, which defeats one of the main advantages of whole blood. A newer generation of platelet-sparing filters has been developed that removes white blood cells while retaining platelet quantity and function. In the United States, whole blood must be filtered and placed in cold storage within 8 hours of collection.¹⁷ Even with platelet-sparing filters, aggregation (the ability of platelets to clump together) drops significantly by day 14 of storage, though some residual platelet activity persists out to 35 days.¹⁸

This shelf-life limitation means blood banks have to manage inventory carefully. Blood is already a challenging product to stock: both supply and demand are unpredictable, a large portion of crossmatched units end up unused by the patient they were reserved for, and waste from expiration is a constant concern.¹⁹ Adding whole blood to the mix, with its shorter optimal window for clotting benefit, requires careful planning. Many programs rotate units that are nearing their platelet-function deadline into the component pathway, separating out still-viable red cells and plasma so nothing goes to waste.

Cost Savings at the Hospital Level

One of the more compelling arguments for whole blood adoption is financial. A community-level trauma center that implemented a whole blood program found striking reductions across the board: a 26% drop in total blood products prepared, about 17% less volume transfused, nearly 39% less product waste, and a 56% reduction in massive transfusion protocol activations. Annual cost savings reached roughly $850,000.²⁰ A separate analysis at another institution found that after introducing whole blood, the mean annual cost of all blood products dropped by about 17%, with an average net difference of over $927,000 per year compared to component therapy alone. Patients receiving whole blood had significantly lower per-patient transfusion costs at every time point measured.²¹

These savings come from multiple sources. Fewer individual products need to be thawed, tested, and prepared. Less waste means fewer donated units go unused. And when patients need fewer total units overall, the entire system is less strained. For hospitals operating on thin margins, these numbers make the operational case for whole blood programs hard to ignore, even setting aside the clinical benefits.

Ethical Challenges in Emergency Research

Studying whole blood rigorously is ethically complicated. The patients who would benefit most are the ones least able to consent to a clinical trial: they’re unconscious, hemorrhaging, and minutes from death. Family members are rarely present in the prehospital environment. Traditional informed consent is impossible in these situations. Since 1996, U.S. regulations have allowed researchers to use an exception from informed consent for studies of life-threatening conditions where getting consent isn’t feasible.²²

The Canadian approach to prehospital transfusion trials has used a model that combines community notification before the trial begins, exception from prospective consent during enrollment, and the option for patients to withdraw after the fact. This was the framework used for a pilot randomized trial of whole blood in frontline trauma in Canada.²³ These ethical frameworks matter because without them, high-quality randomized trials of whole blood in the most critical settings would be nearly impossible to conduct. Much of the current evidence comes from retrospective studies and observational data, which is why the results, while encouraging, carry more uncertainty than researchers would like.

Artificial Alternatives on the Horizon

Even as whole blood programs expand, researchers have been pursuing artificial substitutes that could sidestep the problems of donor dependency, blood typing, short shelf life, and cold-chain logistics entirely. Two main approaches have been explored for decades. Hemoglobin-based oxygen carriers extract or synthesize the hemoglobin molecule and package it in a form that can circulate in the bloodstream without red blood cells. Perfluorocarbon-based carriers are entirely synthetic compounds that can dissolve and transport oxygen. More recent technologies include lab-made molecules that mimic hemoglobin’s function and oxygen-carrying micro- or nanobubbles.²⁴

None of these have replaced real blood in routine clinical use. Earlier generations of hemoglobin-based products ran into safety problems, including vasoconstriction (narrowing of blood vessels) and organ toxicity. A more recently developed hemoglobin-based carrier has shown enough promise in early clinical trials to receive orphan drug designation from the FDA, which provides incentives for developing treatments for rare or underserved conditions.²⁵ Even if one of these products eventually succeeds, it would likely serve as a bridge therapy, buying time until real blood becomes available, rather than a true replacement for whole blood’s full complement of cells, proteins, and clotting factors.